NCT02146313

Who might be able to join this trial:

• Doctors expect you to live for at least 12 weeks
• You are able to carry out normal daily activities with little or no limitation (confirm with trial site for exact definition)
• You have at least one measurable area of disease that can be seen on a CT or MRI scan, meeting specific size requirements (confirm with trial site)
• Your blood counts, kidney function, and liver function are at acceptable levels
• You are using highly effective birth control as defined by the trial
• For ovarian cancer patients: You have been diagnosed with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, confirmed by tissue testing
• For ovarian cancer patients: Your cancer shows a specific protein marker called MUC16, shown either through a blood test (CA125) or tissue testing
• For ovarian cancer patients: Your cancer got worse during or within 6 months of your most recent platinum-based chemotherapy treatment, confirmed by scan
• For ovarian cancer patients (certain groups only): You have had no more than two prior chemotherapy treatments for platinum-resistant ovarian cancer
• For pancreatic cancer patients: You have been diagnosed with advanced or spreading pancreatic ductal adenocarcinoma that cannot be removed by surgery, confirmed by tissue testing
• For pancreatic cancer patients: Your cancer shows the MUC16 protein marker, confirmed by tissue testing
• For pancreatic cancer patients: You have already received standard chemotherapy treatment, and no further standard treatments are available to you
• For pancreatic cancer patients: You have had no more than two prior chemotherapy treatments for pancreatic cancer

Who may not be able to join:

• You have received cancer treatments (such as chemotherapy, biological therapy, experimental therapy, or hormonal therapy) within the 4 weeks before starting the trial
• You have previously been treated with therapies that specifically target the MUC16 protein (such as oregovomab or abagovomab), including a drug called DMUC5754A
• You have previously received a type of drug called an MMAE-containing antibody-drug conjugate (confirm with trial site)
• You have had radiation treatment to bone metastases within the 2 weeks before starting the trial
• You have previously had radiation treatment to your lungs
• You have had a major surgery within 4 weeks before starting the trial
• You currently have an active infection (such as bacterial, viral, or fungal), including HIV, or you were hospitalised for a serious infection within the 4 weeks before starting the trial
• You have significant uncontrolled health conditions such as eye problems, diabetes, heart disease, nerve disorders, kidney, liver, hormone, or digestive disorders, autoimmune disease, or a wound or fracture that is not healing
• You have significant lung or breathing problems, an active lung infection, or your blood oxygen levels are below acceptable levels (confirm with trial site for full details)
• You have a significant history of liver disease, including hepatitis, cirrhosis, or current alcohol misuse
• You have had another cancer in the last 5 years, with some exceptions such as certain treated skin cancers or cervical changes (confirm with trial site)
• You have untreated or currently active cancer that has spread to the brain or spinal cord (those with previously treated brain metastases may still be eligible — confirm with trial site)
• You are currently experiencing side effects from previous cancer treatment above a mild level, or have nerve damage above a mild level from any cause
• You have had a severe allergic reaction to a monoclonal antibody treatment in the past
• You are pregnant or breastfeeding
• You are unable to follow the study requirements and attend follow-up visits
• You have any other condition or finding that your doctor believes could make the trial treatment unsafe for you or affect the trial results

Important: Always verify eligibility with the trial site directly before applying.